Testing a Swallowable Heat-Sensing Capsule in Crohn's Disease and Healthy Adults
Tests a swallowable heat-sensing capsule in adults with Crohn's or healthy adults.
Plain-language title generated from the registry record
Registry title: Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance
Key facts
- Where
- Boston, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07033208, who can take part
Where in United States
- Massachusetts General HospitalBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Massachusetts General Hospital
- Trial code
- NCT07033208
- Record updated
- 2 October 2026
- Original description
The goal of this research is to learn how a new device called the wireless thermal capsule (WTC) can collect thermal data to help see diseases that happen in the gastrointestinal (GI) tract, such as Crohn's Disease.Read full original descriptionShow less
Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance
The goal of this research is to learn how a new device called the wireless thermal capsule (WTC) can collect thermal data to help see diseases that happen in the gastrointestinal (GI) tract, such as Crohn's Disease.
Inclusion: Participant is 18 -75 years old; Participant is considered healthy, with no known illnesses; Participant can follow fasting requirements; Participant can follow bowel prep instructions; Participant can provide informed consent.
Exclusion: Participant with chronic usage of nonsteroidal anti-inflammatory drugs (NSAIDs); Participant who has had intestinal surgery in the past; Participant has participated in an investigational drug or device research study within 30 days of enrollment that may interfere with the subject's safety or ability to participate in this study; Participant with current dysphagia or any swallowing disorder; Participant with any current condition believed to have an increased risk of capsule retention such as gastrointestinal strictures, intestinal tumors, bowel obstruction, incomplete colonoscopies or fistula; Participant with a history of inflammatory bowel disease (IBD), intestinal Crohn's disease, chronic constipation, or rectal bleeding; Participant with a history of congestive heart failure; Participant with Type I or Type II Diabetes; Participant has a cardiac pacemaker or other implanted electromedical device; Participant with clinical evidence of renal disease, including clinically significant laboratory abnormalities of renal function within the past 6 months; Participant is older than 75 years of age; Participant with a diagnosis of gastroparesis or small bowel or large bowel dysmotility; Participants with a known contradiction to metoclopramide; Participants with a known contraindication to polyethylene glycol; Participant with currently suspected or diagnosed with hematochezia, melena, iron deficiency with or without anemia; Participant expected to undergo MRI examination within 7 days after ingestion of the capsule; Participant with delayed gastric emptying; Participant who is pregnant, suspected pregnant, or is actively breast-feeding.